This is a company that has never made a profit. In fact, it’s never made any money at all. On top of that, analysts expect its per-share losses to double by the end of 2022. Assuming Adagio manages to generate some revenues next year — the market consensus is a minuscule $151 million — it’s already trading at almost 20 times those sales. Why? Because COVID is here to stay … and the search for a response is moving into new areas … quickly.
Vax In The Saddle Again I leave for a week of vacation, and I come back to … this? COVID-19 cases...
Read More
May The Pfourth Be With You Great Ones, I don’t know if we officially have a winner in the...
Read More
(4-minute read) The new crop of mRNA vaccines is a testament to scientific achievement in health care. They’re part of a much larger trend that we’ve been monitoring for a while. Here’s how to profit…
Long Train Runnin’ Down around the corner, half a mile from here … see them tech gains run, and...
Read More
Research Analyst
Director of Investment Research
Editor of Strategic Fortunes and two elite services
Director of VIP Services
Editor of Alpha Investor
Sr. Managing Editor of Winning Investor Daily
Chief Editor of True Options Masters
Director of Total Wealth Fellowship
Editor of One Trade and Precision Profits
Senior Managing Editor